Status: Recruiting
A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients
The purpose of this study is to investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TCD601 (siplizumab) in newly diagnosed adult ALS patients.
Participants needed: 48
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: ITB-Med LLCUpdated: Mar 31, 2026Locations: 3
Eligibility criteria
Male or female patients ≥ 18 to 80 years of age. [+2]
Patient with severe systemic infections, current or within the two weeks prior t... [+3]